GABAA receptor subunit expression changes in the human Alzheimer's disease hippocampus, subiculum, entorhinal cortex and superior temporal gyrus
GABAA receptor subunit expression changes in the human Alzheimer's disease hippocampus, subiculum, entorhinal cortex and superior temporal gyrus
复制标题
DOI:
10.1111/jnc.14325
复制
发表时间:
2018-06-01
影响因子:
4.7
通讯作者:
Faull, Richard L.
中科院分区:
文献类型:
--
作者:
Kwakowsky, Andrea;Guzman, Beatriz Calvo-Flores;Faull, Richard L.
Gamma-aminobutyric acid (GABA) is the primary inhibitory neurotransmitter in the central nervous system. GABA type A receptors (GABA(A)Rs) are severely affected in Alzheimer's disease (AD). However, the distribution and subunit composition of GABA(A)Rs in the AD brain are not well understood. This is the first comprehensive study to show brain region- and cell layer-specific alterations in the expression of the GABA(A)R subunits 1-3, 5, 1-3 and 2 in the human AD hippocampus, entorhinal cortex and superior temporal gyrus. In late-stage AD tissue samples using immunohistochemistry we found significant alteration of all investigated GABA(A)Rs subunits except for 3 and 1 that were well preserved. The most prominent changes include an increase in GABA(A)R 1 expression associated with AD in all layers of the CA3 region, in the stratum (str.) granulare and hilus of the dentate gyrus. We found a significant increase in GABA(A)R 2 expression in the str. oriens of the CA1-3, str. radiatum of the CA2,3 and decrease in the str. pyramidale of the CA1 region in AD cases. In AD there was a significant increase in GABA(A)R 5 subunit expression in str. pyramidale, str. oriens of the CA1 region and decrease in the superior temporal gyrus. We also found a significant decrease in the GABA(A)R 3 subunit immunoreactivity in the str. oriens of the CA2, str. granulare and str. moleculare of the dentate gyrus. In conclusion, these findings indicate that the expression of the GABA(A)R subunits shows brain region- and layer-specific alterations in AD, and these changes could significantly influence and alter GABA(A)R function in the disease.